Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 262

1.

The necessity for rigour in rare disease study design.

Baker LH.

Lancet Oncol. 2019 Sep;20(9):1190-1192. doi: 10.1016/S1470-2045(19)30323-7. Epub 2019 Jul 19. No abstract available.

PMID:
31331700
2.

Patient Perceptions of Survivorship Care Plans: A Mixed-Methods Evaluation.

Antalis EP, Doucette R, Kuhn G, Baker LH, Reinke D.

Oncol Nurs Forum. 2019 Jul 1;46(4):493-502. doi: 10.1188/19.ONF.493-502.

PMID:
31225833
3.

In Memoriam: Charles A. Coltman, 1930 to 2018.

Blanke CD, Crowley J, Baker LH, Fisher RI.

J Clin Oncol. 2019 May 1;37(13):1037-1040. doi: 10.1200/JCO.19.00270. Epub 2019 Mar 12. No abstract available.

PMID:
31026409
4.

Primary Cardiac Sarcoma: A Rare, Aggressive Malignancy with a High Propensity for Brain Metastases.

Siontis BL, Zhao L, Leja M, McHugh JB, Shango MM, Baker LH, Schuetze SM, Chugh R.

Sarcoma. 2019 Mar 10;2019:1960593. doi: 10.1155/2019/1960593. eCollection 2019.

5.

Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices.

Ramsey SD, Unger JM, Baker LH, Little RF, Loomba R, Hwang JP, Chugh R, Konerman MA, Arnold K, Menter AR, Thomas E, Michels RM, Jorgensen CW, Burton GV, Bhadkamkar NA, Hershman DL.

JAMA Oncol. 2019 Apr 1;5(4):497-505. doi: 10.1001/jamaoncol.2018.6437. Erratum in: JAMA Oncol. 2019 Mar 7;:.

PMID:
30653226
6.

Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.

Schuetze SM, Bolejack V, Thomas DG, von Mehren M, Patel S, Samuels B, Choy E, D'Amato G, Staddon AP, Ganjoo KN, Chow WA, Rushing DA, Forscher CA, Priebat DA, Loeb DM, Chugh R, Okuno S, Reinke DK, Baker LH.

JAMA Oncol. 2018 Jun 1;4(6):814-820. doi: 10.1001/jamaoncol.2018.0601.

7.

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S.

Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Erratum in: Lancet Oncol. 2018 Jan;19(1):e8.

PMID:
28988646
8.

Integrative clinical genomics of metastatic cancer.

Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, Schuetze S, Alva A, Siddiqui J, Chugh R, Worden F, Zalupski MM, Innis J, Mody RJ, Tomlins SA, Lucas D, Baker LH, Ramnath N, Schott AF, Hayes DF, Vijai J, Offit K, Stoffel EM, Roberts JS, Smith DC, Kunju LP, Talpaz M, CieĊ›lik M, Chinnaiyan AM.

Nature. 2017 Aug 17;548(7667):297-303. doi: 10.1038/nature23306. Epub 2017 Aug 2.

9.

Reduced infectivity of waterborne viable but nonculturable Helicobacter pylori strain SS1 in mice.

Boehnke KF, Eaton KA, Fontaine C, Brewster R, Wu J, Eisenberg JNS, Valdivieso M, Baker LH, Xi C.

Helicobacter. 2017 Aug;22(4). doi: 10.1111/hel.12391. Epub 2017 Apr 24.

10.

Next generation sequencing of extraskeletal myxoid chondrosarcoma.

Davis EJ, Wu YM, Robinson D, Schuetze SM, Baker LH, Athanikar J, Cao X, Kunju LP, Chinnaiyan AM, Chugh R.

Oncotarget. 2017 Mar 28;8(13):21770-21777. doi: 10.18632/oncotarget.15568.

11.

Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru.

Boehnke KF, Valdivieso M, Bussalleu A, Sexton R, Thompson KC, Osorio S, Novoa Reyes I, Crowley JJ, Baker LH, Xi C.

Infect Drug Resist. 2017 Mar 10;10:85-90. doi: 10.2147/IDR.S123798. eCollection 2017.

12.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.

Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH.

JAMA Oncol. 2017 Jul 1;3(7):944-952. doi: 10.1001/jamaoncol.2016.6728. Erratum in: JAMA Oncol. 2017 Jul 1;3(7):1002.

13.

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.

Schuetze SM, Bolejack V, Choy E, Ganjoo KN, Staddon AP, Chow WA, Tawbi HA, Samuels BL, Patel SR, von Mehren M, D'Amato G, Leu KM, Loeb DM, Forscher CA, Milhem MM, Rushing DA, Lucas DR, Chugh R, Reinke DK, Baker LH.

Cancer. 2017 Jan 1;123(1):90-97. doi: 10.1002/cncr.30379. Epub 2016 Oct 3.

14.

Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival.

Koshkin VS, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, Zhao B, O JH, Patel SR, Schuetze SM, Baker LH.

J Clin Oncol. 2016 Oct 20;34(30):3680-3685. doi: 10.1200/JCO.2016.68.1858.

15.

SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy.

Davis EJ, Zhao L, Lucas DR, Schuetze SM, Baker LH, Zalupski MM, Thomas D, Chugh R.

BMC Cancer. 2016 Aug 20;16:663. doi: 10.1186/s12885-016-2694-2.

16.

The University of Michigan Sarcoma Survivorship Clinic: Preventing, Diagnosing, and Treating Chronic Illness for Improved Survival and Long-Term Health.

Bobowski NP, Baker LH.

J Adolesc Young Adult Oncol. 2016 Sep;5(3):211-4. doi: 10.1089/jayao.2016.0004. Epub 2016 Apr 26.

17.

Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group.

Bennette CS, Veenstra DL, Basu A, Baker LH, Ramsey SD, Carlson JJ.

Med Decis Making. 2016 Jul;36(5):641-51. doi: 10.1177/0272989X16636847. Epub 2016 Mar 24.

18.

Contemporary Concerns in Managing Bone Sarcoma.

Baker LH.

J Oncol Pract. 2016 Mar;12(3):217-8. doi: 10.1200/JOP.2015.010181. No abstract available.

PMID:
26962161
19.

The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.

Bid HK, Phelps DA, Xaio L, Guttridge DC, Lin J, London C, Baker LH, Mo X, Houghton PJ.

Mol Cancer Ther. 2016 May;15(5):1018-28. doi: 10.1158/1535-7163.MCT-15-0567. Epub 2016 Feb 23.

20.

Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor.

Hyun O J, Luber BS, Leal JP, Wang H, Bolejack V, Schuetze SM, Schwartz LH, Helman LJ, Reinke D, Baker LH, Wahl RL.

J Nucl Med. 2016 May;57(5):735-40. doi: 10.2967/jnumed.115.162412. Epub 2016 Jan 21.

Supplemental Content

Loading ...
Support Center